TM TMO Thermo Fisher Scientific Loading... : Bullish and Bearish Analyst Opinions

Author notes healthcare stocks are setting up in a strong uptrend and lists XLV's top holdings.

Quality healthcare names attract rotation

Piper Sandler raises Thermo Fisher Scientific price target to 600 dollars from 510 dollars.

Thermo Fisher Scientific raised its revenue forecast after stronger-than-expected spending.

Thermo Fisher Scientific reported strong second quarter 2026 results with broad-based growth.

Pre-market movers report shows sharp declines in Google and Tesla after earnings while Now, CSX.

Thermo Fisher reports Q2 2026 adjusted EPS of 6.03 dollars on revenue of 11.99 billion dollars.

Thermo Fisher reported second quarter 2026 adjusted earnings per share of 6.03 dollars.

Thermo Fisher reported adjusted earnings per share of 6.03 dollars on revenue of 11.99 billion.

Management raised both revenue and EPS guidance, citing stronger customer activity and execution, with an improved outlook for the rest of the year.

Vague bullish comment without specific reason or catalyst; no actionable thesis.

Quality stocks unusually cheap now.

Speaker describes a bull case thesis for TMO/DHR involving a pivot to semis.

The author implies that non-AI names are broken and will be crushed to zero multiples.

The author expresses frustration with market valuations and poses a rhetorical question about.

The author poses a rhetorical question about valuation multiples for non-AI names versus.

AI-assisted drug discovery companies typically work on many more programs simultaneously than traditional biotechs, which could increase the volume of preclinical work that gets outsourced to CRL. — As AI-native drug developers scale, they are more likely to outsource their 'wet lab' work, creating a new and potentially larger pipeline of customers for contract research organizations.

TMO cheap at 19x earnings.

The author compares current semiconductor mania to the COVID-era biopharma bubble.

The author compares current semiconductor mania to the COVID-era life sciences bubble.

TMO (#7 in XLV) “has moved sideways for 5 years,” underperforming despite steady earnings growth from life sciences tools. A multi‑year consolidation often precedes a breakout; sector re‑rating would finally reward TMO’s fundamental stability. Thermo Fisher offers exposure to healthcare innovation (lab equipment, diagnostics) at a compressed valuation relative to its historical multiples. Slowing biopharma capex, post‑pandemic demand normalization, or geopolitical disruption to supply chains.

The author is bullish on bioprocessing and specifically recommends $DIM.FP as a long position.

Watch TMO; stable life sciences and diagnostics; no material positive surprise from Sanmina’s.

Thermo Fisher selloff is overdone.

Management raised full-year guidance after a solid Q1, citing strong operational performance and confidence in end-market resilience despite macro headwinds.

The author suggests that the life sciences sector has reached a market floor.

The tweet implies positive growth prospects for the bioprocessing sector.

I just came from Thermo Fisher Scientific investing $2 billion in domestic manufacturing. Ford Motor Company announced a $2 billion assembly plant. Apple is spending $650 billion on new plants. GE Aerospace announced a $1 billion investment. All because of what we've done with the tariffs and with the deductions. Companies that aggressively onshore their supply chains and build domestic factories are the primary beneficiaries of the administration's America First industrial policy. 100% upfront expensing and tariff protections give these specific domestic manufacturers a structural margin and tax advantage over import-reliant competitors. LONG. These mega-caps are perfectly aligned with the administration's tax and trade policies, ensuring favorable regulatory treatment and lower effective tax rates. Retaliatory tariffs from foreign nations could negatively impact their international revenue streams.

Agilent's services agreements with nearly all top-20 biopharma companies provide a 'flywheel' effect, embedding Agilent engineers on-site and giving Agilent early visibility into customers' instrument replacement cycles, allowing it to pre-empt competitors. — Agilent's deepening service relationships could structurally lock in long-term revenue and give it an edge in capital equipment and consumables purchasing decisions against rivals.

Management highlights the incoming CEO's experience at Thermo Fisher, implicitly endorsing that company's operational playbook as a model for Henry Schein's own growth strategy.